Important Information for Health Care Providers

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

This patient is being treated with retifanlimab, which can cause immune-related adverse reactions that may appear any time during treatment or even after treatment. Assess patients for signs and symptoms of immune-related adverse reactions. Early diagnosis and appropriate management are essential to minimise any consequences of immune-related adverse reactions.

Specific guidelines for managing immune-related adverse reactions are available in the Summary of Product Characteristics for retifanlimab (www.medicines.org.uk/emc).

Consultation with an oncologist or other medical specialist may be helpful for management of organ-specific immune-related adverse reactions.

You can report side effects directly via the Yellow Card Scheme at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store. You can also report to the Marketing Authorisation Holder, Incyte, by calling 00-800-0002-7423.

For further details, please consult the package leaflet for patient information or visit www.incyteglobalmedicalinformation.com or contact Incyte Medical Information at +800 00027423 or eumedinfo@incyte.com.

Contact your specialist right away if you develop any signs or symptoms, including those not listed on this card. Your doctor may give you other medicines in order to prevent more severe complications and reduce your symptoms. Your doctor may withhold the next dose or stop treatment.

IIMPORTANT

- Do not attempt to treat side effects yourself
- Do not stop your treatment with retifanlimab unless you have discussed this with your doctor
- Symptoms are sometimes delayed and may occur weeks or months after your last dose
- If you experience any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this card

CARRY THIS CARD WITH YOU AT ALL TIMES

- **Show this card to any healthcare professional involved in your care**
- Take it with you when travelling, anytime you go to the Accident or Emergency department or when you need to see another doctor

UK/ZYN/NP/26/0001
Version 1.0, October 2026

PATIENT CARD

Zynyz®▼ (retifanlimab)

Important safety information to minimise the risk of immune-related adverse reactions

May cause serious side effects, which can sometimes become life-threatening and lead to death. These may happen any time during treatment or even after your treatment has ended. You may experience more than one side effect at the same time.

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may experience.

You can report side effects directly via the Yellow Card Scheme at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store. You can also report to the Marketing Authorisation Holder, Incyte, by calling 00-800-0002-7423.

This risk minimisation material fulfils the conditions of the marketing authorisation and has been approved by the competent authority.

Tell your doctor right away if you have any of these symptoms:

Lungs
- Breathing difficulties
- New or worsening cough
- Chest pain

Intestines
- Frequent diarrhoea often with blood and/or mucus
- More bowel movements than usual
- Stools that are bloody, black or tarry
- Severe abdominal pain or tenderness

Liver
- Persistent nausea or vomiting
- Pain on the right side of stomach
- Eye and/or skin yellowing
- Drowsiness
- Dark-coloured urine
- Bleeding or bruising more easily than normal

Kidneys
- Decreased volume of urine
- Passing blood or traces of blood in the urine that may change its colour
- Swollen ankles

Hormone glands
- Fast heartbeat
- Dizziness or fainting
- Extreme tiredness
- Persistent or unusual headaches
- Weight change
- Feeling cold
- Hair loss
- Constipation

Type 1 diabetes or diabetic ketoacidosis
- Feeling more hungry or thirsty than usual
- Frequent urination
- Weight loss
- Feeling tired or sick
- Difficulty thinking clearly
- Fast and deep breathing
- Breath that smells sweet or fruity
- Sweet or metallic taste in the mouth
- Stomach pain
- Sleepiness
- Different odour to urine or sweat

Skin
- Rash or itching
- Skin blistering or ulcers in the mouth or in the lining of the nose, throat or genital area

Nervous system
- Numbness or weakness
- Tingling or numbness of the hands or feet
- Pinched nerve caused by damage to the nerve root in the spine
- Nerve damage to the voice box used for breathing, swallowing and talking

Other organs
- Changes in eyesight

Important contact information

Name of doctor

Office phone number

Out-of-hours phone number

My name

My phone number

Emergency contact (name)

Emergency contact (phone number)

This card is intended for UK patients who have been prescribed retifanlimab.